HIV/AIDS
New research on HIV/AIDS from Chelsea and Westminster Hospital NHS Trust summarized
Published in AIDS Weekly, January 5th, 2009
According to recent research published in the journal AIDS Research and Human Retroviruses, "Data from two Phase IIb trials, POWER 1 and 2 (TMC114-C213 and C202), were pooled to examine the effect of baseline viral susceptibility on response to control protease inhibitors [CPI(s)] compared with response to darunavir (TMC114) given with low-dose ritonavir (darunavir/r) in treatment-experienced HIV patients. POWER 1 and 2 were randomized, controlled Phase IIb trials with a similar design."
"Patients with one or more primary PI mutations and HIV-1 RNA > 1000 copies/ml were randomized to receive an optimized background regimen plus darunavir/r or CPI(s). POWER 1...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2009-01-05)
More Articles from AIDS Weekly
- Saint Louis University
Using math to understand hep. C: Patterns paint picture of who will respond to treatment - Stanford University Medical Center
Mouse trap? Stanford immunologist calls for more research on humans, not mice - HIV/AIDS
New HIV/AIDS study findings have been reported from J.S. Affandi et al - HIV/AIDS
Reports on HIV/AIDS findings from J.A. Mira and co-researchers provide new insights - HIV/AIDS
Researchers at New York Blood Center release new data on HIV/AIDS - HIV/AIDS
Researchers from University College report recent findings in HIV/AIDS - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
